Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485428 | 1.00 | KIT (0.44) | KITGRM1PIK3CDL3MBTL1CHRM1 | |
| SCHEMBL5482960 | 0.89 | GRM1 (0.51) | KITGRM1PIK3CDL3MBTL1KDM4E | |
| SCHEMBL5482964 | 0.89 | GRM1 (0.51) | KITGRM1PIK3CDL3MBTL1KDM4E | |
| SCHEMBL5486552 | 0.88 | GRM1 (0.42) | KITGRM1PIK3CDL3MBTL1CHRM1 | |
| SCHEMBL5480673 | 0.88 | CHRM1 (0.42) | KITGRM1PIK3CDL3MBTL1CHRM1 | |
| SCHEMBL5486546 | 0.88 | GRM1 (0.42) | KITGRM1PIK3CDL3MBTL1CHRM1 | |
| SCHEMBL5480665 | 0.88 | CHRM1 (0.42) | KITGRM1PIK3CDL3MBTL1CHRM1 | |
| SCHEMBL5481574 | 0.87 | CHRM1 (0.42) | KITGRM1L3MBTL1CHRM1CHRM2 | |
| SCHEMBL5481568 | 0.87 | CHRM1 (0.42) | KITGRM1L3MBTL1CHRM1CHRM2 | |
| SCHEMBL5484705 | 0.85 | KIT (0.44) | KITGRM1PIK3CDL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | KIT 2227/4885GRM1 2/4885PIK3CD 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.